CJC-1295 + Ipamorelin Information & Coordination for Licensed U.S. Clinics
CJC-1295-related and ipamorelin-related bulk drug substances have been evaluated by FDA in the context of pharmacy compounding.
FDA’s review states that the CJC-1295 forms it evaluated are not components of FDA-approved drugs. FDA reached the same conclusion for ipamorelin free base and ipamorelin acetate.
Phoenix Meds Inc. provides licensed healthcare organizations with administrative support around credential review, documentation, and publicly available regulatory information.
We are not a pharmacy, medical practice, manufacturer, prescriber, or dispensing entity.
What Clinics Should Know About CJC-1295 and Ipamorelin
The names “CJC-1295” and “ipamorelin” should not be treated as though they describe a single standardized, FDA-approved medication.
FDA evaluated several distinct CJC-1295-related substances, including free-base, acetate, and DAC forms. The agency also noted inconsistent naming conventions in the available records and explained that the different substances are not necessarily interchangeable.
For ipamorelin, FDA separately evaluated ipamorelin free base and ipamorelin acetate. Neither has an applicable USP/NF drug-substance monograph, and neither is a component of an FDA-approved drug.
Phoenix does not present CJC-1295 + ipamorelin as an FDA-approved therapy or promote it for anti-aging, body composition, athletic performance, wellness, or other treatment outcomes.
Current FDA and Compounding Status
FDA reviewed CJC-1295-related bulk drug substances for possible inclusion on the section 503A Bulks List in 2024.
The agency proposed not adding CJC-1295 free base, CJC-1295 acetate, CJC-1295 DAC free base, CJC-1295 DAC acetate, or CJC-1295 DAC trifluoroacetate to that list. The Pharmacy Compounding Advisory Committee subsequently voted against including the evaluated CJC-1295 forms.
FDA separately evaluated ipamorelin free base and ipamorelin acetate and concluded that the available criteria weighed against placing either substance on the 503A Bulks List. The advisory committee also voted against their inclusion.
Those advisory proceedings should not be described as a final rule by themselves. FDA continues to develop the 503A Bulks List through its regulatory process, so clinics should check current agency information before relying on a particular compounding pathway.
A pharmacy’s 503A status or an outsourcing facility’s 503B registration also does not, by itself, establish that a particular bulk substance may be used in compounding. Different statutory requirements apply to the substance and the circumstances involved.
Why Product Identity Matters
This is particularly important with CJC-1295.
FDA found inconsistencies in the naming and characterization of CJC-1295-related substances. Its review identified multiple chemically distinct forms and noted that confusion over identity could create safety concerns.
A clinic reviewing information about these substances should therefore understand exactly what substance is being referenced and what documentation supports that identity.
Phoenix can help organize that information, but we do not determine clinical suitability or make a legal determination about whether a specific preparation may be compounded.
How Phoenix Meds Supports Licensed Clinics
Our work is administrative.
For licensed healthcare organizations, that may include reviewing professional credentials, organizing supporting records, checking publicly available licensing and regulatory information, and helping identify documentation questions that need further review.
We can also help clinics separate what is documented from what is simply being claimed about a product or entity.
The purpose is to make the review process easier to follow while keeping clinical, pharmaceutical, and legal responsibilities with the professionals responsible for them.
Phoenix’s administrative review is not FDA approval, pharmacy accreditation, a legal opinion, or confirmation that a particular preparation or transaction is permitted.
Safety and Documentation Considerations
FDA has identified potential safety concerns involving CJC-1295 and ipamorelin acetate in the compounding context.
For CJC-1295, FDA cites concerns involving immunogenicity, peptide-related impurities, API characterization, limited clinical data, and reported serious adverse events.
For ipamorelin acetate, FDA identifies potential concerns involving aggregation, peptide-related impurities, and limited safety information for certain routes of administration.
Phoenix does not manufacture, test, compound, dispense, ship, or take custody of these substances. We also do not certify their purity, potency, sterility, authenticity, safety, or clinical suitability.
CJC-1295 + Ipamorelin Administrative Coordination for Licensed Clinics
Clinic Verification
Professional and facility credentials may be reviewed as part of Phoenix’s administrative process.
Documentation Review
Phoenix may help organize available documentation and publicly available regulatory information so the clinic can identify issues requiring further review.
Licensed Parties
Prescribing, compounding, dispensing, distribution, storage, shipping, and other regulated medication activities remain with the parties legally authorized and responsible for performing them.
Frequently Asked Questions
Are CJC-1295 and ipamorelin FDA approved?
FDA’s review states that none of the CJC-1295-related bulk drug substances it evaluated is a component of an FDA-approved drug. FDA also states that ipamorelin free base and ipamorelin acetate are not components of FDA-approved drugs.
Is CJC-1295 + ipamorelin an FDA-approved combination product?
FDA’s materials reviewed for this page do not identify an FDA-approved CJC-1295 + ipamorelin combination drug product.
Are these substances on the 503A Bulks List?
FDA evaluated the CJC-1295 and ipamorelin substances discussed above and proposed that they not be added to the 503A Bulks List. Because the list is developed through an ongoing regulatory process, current FDA information should be checked before relying on a particular status.
Does Phoenix compound or dispense CJC-1295 + ipamorelin?
No. Phoenix Meds Inc. does not compound, manufacture, dispense, test, ship, or take custody of these substances.
What does Phoenix Meds help clinics with?
Our role is administrative and may include credential review, documentation organization, review of publicly available regulatory information, and compliance-focused communication.
Does Phoenix provide dosing or treatment protocols?
No. We do not provide patient-specific dosing, treatment protocols, or medical recommendations.
Important Notice
Phoenix Meds Inc. provides administrative coordination, documentation, and compliance-focused support for licensed healthcare organizations.
We are not a pharmacy, medical practice, drug manufacturer, outsourcing facility, prescriber, or dispensing entity.
This page is intended for professional informational purposes. It does not present CJC-1295 or ipamorelin as FDA-approved treatments and does not establish that a particular compounding or distribution pathway is available or permitted.
Regulatory References
- December 4, 2024 Pharmacy Compounding Advisory Committee — CJC-1295-Related Bulk Drug Substances
- CJC-1295-Related Bulk Drug Substances — FDA Briefing Document
- October 29, 2024 Pharmacy Compounding Advisory Committee — Ipamorelin
- Ipamorelin — FDA Briefing Document
- Certain Bulk Drug Substances for Use in Compounding That May Present Significant Safety Risk
- Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act